Patent application: cancer stem cell vaccine technology

ImmunoCellular Therapeutics Announces Filing Of Patent Application For A Novel Cancer Stem Cell Vaccine Technology, Medical News Today, October 12, 2008. The first paragraph:

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) (IMUC), a biotechnology company, announced the filing of a provisional U.S. patent application relating to its novel vaccine technology targeting cancer stem cells. The vaccine technology is exclusively licensed from Cedars-Sinai Medical Center. The patent claims are broad and include compositions of peptides for cancer immunotherapy as well as methods for inducing immune responses against tumor antigens in cancer patients.